Esperion reports 30% MACE-4 risk reduction with bempedoic acid in primary prevention CLEAR Outcomes subanalysis

Esperion Therapeutics, Inc.

Primary prevention population (4,206 statin-intolerant patients) showed 30% risk reduction in MACE-4 (HR 0.70) vs placebo.
36% MACE-3 risk reduction (HR 0.64) and 39% reduction in CV mortality (HR 0.61).
All-cause mortality reduced by 27% (HR 0.73). LDL-C lowered 21.3% after 6 months; hsCRP lowered 21.5% after 12 months.
Data presented at ADA 2023 and simultaneously published in JAMA on June 24, 2023.
Nearly two-thirds (66.1%) of primary prevention patients had diabetes; safety consistent with prior trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.